AngioDynamics Stock News

AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand

AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. The recent approval of the AlphaV

Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.

AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.

AngioDynamics Inc. (NASDAQ:ANGO ) Q3 2024 Earnings Conference Call April 4, 2024 8:00 AM ET Company Participants Jim Clemmer - President, Chief Executive Officer Steve Trowbridge - Executive Vice Pres

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on Febru

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand

AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand

In the most recent trading session, AngioDynamics (ANGO) closed at $5.37, indicating a -0.74% shift from the previous trading day.

In the most recent trading session, AngioDynamics (ANGO) closed at $5.67, indicating a -1.39% shift from the previous trading day.